Advanced Filters
noise
Found 65,447 clinical trials

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in participants with pediatric low-grade glioma (LGG) harboring an activating rapidly accelerated fibrosarcoma (RAF) alteration requiring first-line systemic therapy.

- 25 years of age All Phase 3

Reducing Mortality in Adults With Advanced HIV Disease (REVIVE)

A double blinded, placebo-controlled, multicenter trial to evaluate effectiveness of azithromycin prophylaxis on mortality in advanced HIV.

18 years of age All Phase 3
A Amelia Rudd, HND

Is There a Genetic Predisposition for Acute Stress-induced (Takotsubo) Cardiomyopathy

Acute stress-induced (takotsubo) cardiomyopathy or broken heart syndrome presents like a heart attack, classically is triggered by intense emotional or physical stress and can have serious health consequences. In the current study the investigators wish to establish whether there is a genetic predisposition making certain people more susceptible to this …

years of age All Phase N/A
L Lynn Yee, MD, MPH

Reducing the Risk of Chronic Hypertension and Improving Vascular Function Following Preeclampsia

The long-term goal of our work is to evaluate the effect of intensive postpartum blood pressure control on maternal cardiovascular health, risk of chronic hypertension, and reversal of vascular dysfunction generated by hypertensive disorders of pregnancy, thus attenuating the lifelong trajectory of cardiovascular disease risk.

18 years of age Female Phase N/A
H Heeju Jang-Paulsen

The Effect of Work Requirements in SNAP in Virginia

More than a dozen states have proposed or plan to implement work requirements in Medicaid, and similar requirements already exist nationally in the Supplemental Nutritional Assistance Program (SNAP), yet evidence on the effects of these policies is limited. In cooperation with the state of Virginia, the investigators plan to conduct …

18 - 49 years of age All Phase N/A
S Samantha Westphal, RN,BSN,PHN,CLMS

Minnesota RETAIN Phase 3

MN RETAIN Phase 3 is a non-randomized trial to evaluate the impact of RETAIN program expansion and services on workforce retention and reduction of future workplace disability in the state of MN. The program is funded by US Department of Education (DOE). There will be collaboration between partners to implement …

18 years of age All Phase N/A
s sherihan R. ahmed, MD

Combining Aspirin With Ticagrelor or Cilostazol in Minor Stroke or TIA

Along with the current clinical trial, the efficacy and safety of a 180 mg loading dose of ticagrelor administered within 24 hours of the first-ever minor stroke or TIA compared to 200mg cilostazol were assessed through NIHSS, mRS, and possible adverse effects.

18 - 75 years of age All Phase 3

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug

This is a study to demonstrate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult patients with active psoriatic arthritis who are naive to biologic disease-modifying antirheumatic drug therapy.

18 years of age All Phase 3
J Joseph Opare, PI

Real World Evaluation of an Albendazole-Ivermectin Coformulation Safety and Effectiveness

An open-label, randomized by school, two-arm pragmatic trial, will be conducted involving two study sites in Sub-Saharan-Africa (SSA), Ghana and Kenya, to evaluate safety and effectiveness of the newly developed fixed dose combination (FDC) of albendazole (ALB) and ivermectin (IVM) as a single dose to treat Soil-Transmitted Helminths (STH), compared …

5 - 17 years of age All Phase 3
Y Yongjun Wang

Y-3 for Injection in the Treatment of Acute Ischemic Stroke

This trial aims to evaluate the effectiveness and safety of Y-3 for injection in the treatment of patients with acute ischemic stroke within 48 hours of onset

18 - 81 years of age All Phase 3

Simplify language using AI